Todos os estudos
RecrutamentoFase I e Fase II (Integrado) - OutrosIntervencionista

Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults with Hereditary Angioedema (HAE)

Hereditary angioedema (HAE) is a lifelong genetic condition that causes sudden, severe swelling in different parts of the body, such as the face, hands, gut, or throat. This clinical trial is testing an experimental treatment called NTLA-2002 in adults with HAE. NTLA-2002 uses gene-editing technology to turn down a specific protein in the blood that triggers swelling attacks. The main goals of the study are to check that the treatment is safe, see what side effects it might cause, and find out whether it reduces the number and severity of attacks people experience. The trial has two parts: Phase 1 checks different doses for safety, while Phase 2 tests how well the treatment works compared to a dummy drip (placebo). Taking part is voluntary, and participants will receive regular check-ups and close health monitoring throughout.

Em resumo

Status
Recrutamento
Fase
Fase I e Fase II (Integrado) - Outros
Patrocinador
Intellia Therapeutics Inc.
Meta de inscrição
15
Iniciar
13 May 2024

Sobre o que é este estudo?

Hereditary angioedema (HAE) is a rare genetic condition where the body produces too much of a chemical that causes fluid to leak into tissues. This leads to unpredictable and often painful episodes of swelling in the skin, stomach, and sometimes the airway, which can be dangerous. Current treatments usually involve regular injections to prevent attacks or rescue medicines to treat them when they happen. This trial is investigating a new approach that aims to offer longer-lasting control.

The experimental medicine being tested is called NTLA-2002. It is an innovative gene-editing therapy designed to target and alter a specific gene in liver cells. By doing this, it aims to lower the levels of a protein called prekallikrein, which plays a central role in triggering swelling attacks. The goal is to stop swelling before it starts, potentially from a single treatment.

Because this is an early-stage study (Phase 1/2), the primary focus is participant safety. Doctors want to see how the body handles the medicine, monitor any side effects, and check drug levels in blood and urine samples. As the trial progresses, researchers will also track the number of swelling attacks participants experience to see if the treatment effectively reduces or stops them.

Pontos principais

  • The study tests NTLA-2002, an experimental gene-editing therapy for adults with hereditary angioedema (HAE).
  • It aims to treat the root cause of HAE by reducing the protein that triggers painful swelling attacks.
  • The main goals are to check safety, monitor side effects, and measure reductions in monthly attacks.
  • The treatment is given as an intravenous drip, followed by regular clinic check-ups and monitoring.
  • Participation is voluntary, and you can withdraw at any point without affecting your routine care.

Quem pode ser elegível?

This trial is open to adults aged 18 and over who have been diagnosed with hereditary angioedema (HAE). Both men and women can take part.

Because this is an early study using gene-editing technology, the trial team will look closely at your general health. You may need to have had a certain number of swelling attacks over recent months to help researchers judge whether the treatment works.

People with certain other serious medical conditions, severe liver or kidney problems, or those who are pregnant or planning a pregnancy may not be able to join. The study doctors will review your complete medical history and carry out screening tests to confirm if the trial is suitable for you.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. I am aged 18 or older.
  2. I have a confirmed medical diagnosis of hereditary angioedema (HAE).
  3. I still experience swelling attacks and keep track of when they occur.
  4. I am able and willing to attend regular hospital appointments and provide blood and urine samples.
  5. I am not currently pregnant or planning to become pregnant during the trial.
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

Taking part begins with a screening visit where doctors check your overall health, review your attack history, and perform blood and urine tests. If you are eligible, you will receive the study treatment through an intravenous drip (an infusion into a vein). In the Phase 2 part of the study, some participants will receive the active medicine and others will receive a simple salt-water drip (placebo), though those on placebo may be offered the active medicine later in the study.

After receiving the infusion, you will have regular clinic visits so the medical team can monitor your health, check your vital signs, and collect blood and urine samples. You will also be asked to keep an electronic diary or record to note down any swelling attacks you have, their severity, and whether you needed your normal rescue medication.

Because NTLA-2002 involves gene editing, the study includes a thorough follow-up period lasting several months to track long-term safety and measure how well the treatment works over time.

Riscos e benefícios potenciais

A potential benefit is that NTLA-2002 may significantly reduce or prevent your HAE swelling attacks, and your participation will help advance medical science for people with this condition. However, because this is an experimental therapy, there is no guarantee it will improve your symptoms. There are also risks, including reactions to the infusion, unforeseen side effects from the gene-editing process, and the possibility of receiving a placebo during Phase 2. You will be closely monitored throughout the trial, and you are entirely free to withdraw from the study at any time without your regular NHS or specialist care being affected.

Localizações (3)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    Alemanha
  • —
    Não verificado
    França
  • —
    Não verificado
    Países Baixos

Perguntas frequentes

What is NTLA-2002?

NTLA-2002 is an investigational treatment that uses gene-editing technology (CRISPR) to permanently switch off a specific gene in the liver, reducing the protein that triggers swelling attacks.

Will I definitely receive the active medicine?

In Phase 1, everyone receives the active drug at varying doses. In Phase 2, some people will receive a harmless salt-water dummy drip (placebo) first, but there is an option to receive the real medicine later in the study.

Can I still take my emergency rescue medication if I have an attack?

Yes. Your safety comes first, and you will still be able to use your approved emergency rescue treatments if you experience a swelling attack during the study.

How is the treatment given?

NTLA-2002 is given as a single intravenous drip into a vein, usually done in a hospital clinic under close medical observation.

Do I have to pay to take part?

No, clinical trial medicines and study-related tests are provided free of charge, and travel expenses for hospital visits are usually reimbursed.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacoki…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.